 | |
| Nasdaq: PGEN Russell 2000 Component | |
| Industry | Biotechnology |
| Founded | May 21, 1998 |
| Headquarters | , US |
| Revenue |  $91 million (2019)[1] |
Number of employees | 600 |
| Website | precigen |
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.[2][3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[4]
YouTube Encyclopedic
-
1/3Views:4181 38254 900
-
The Smart Money Are Looking at: Precigen
-
Stock $PGEN / NASDAQ (Precigen) | Trading Algorithm
-
Penny Stocks to Buy Now: Stocks to Buy NOW!
Transcription
History
In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million.[5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.[6][7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[8][9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.[7]
See also
References
- ^ "Precigen Revenue 2012-2021 | PGEN".
- ^ "Intrexon Corporation: Private Company Information". Bloomberg. Retrieved 2017-06-26.
- ^ "Intrexon Corp (XON) Company Profile". Reuters.com. Retrieved 2017-06-26.[dead link]
- ^ "FAQ | Intrexon". Intrexon InvestorRoom. Retrieved 2018-03-28.
- ^ Nickel, Rod (15 September 2015). "Market turbulence or not, North American investors plow into farm tech". Reuters. Retrieved 9 October 2015.
- ^ "PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS". FDA. Retrieved 6 April 2020.
- ^ a b Gilgore, Sara (6 January 2020). "Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug". American City Business Journals. Retrieved 6 April 2020.
- ^ "INTREXON CORPORATION IS NOW PRECIGEN, INC". Precigen. Retrieved 6 April 2020.
- ^ Helmstetter, Michael (30 March 2020). "The Promise And Fear Of Gene Editing". Forbes. Retrieved 6 April 2020.
